Tonix Pharmaceuticals to Present TONMYA Phase 3 Analysis at IASP Pain Congress

Bitget2026/10/19 11:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tonix Pharmaceuticals will present a Phase 3 TONMYA analysis October 27, 2026, at the IASP World Congress on Pain in Bangkok.
The analysis indicates reduced fibromyalgia impact on physical symptoms and functional ability.
TONMYA received FDA approval for adult fibromyalgia August 15, 2025; its U.S. commercial launch followed November 17, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190700PRIMZONEFULLFEED9847773) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tonix Pharmaceuticals to Present TONMYA Phase 3 Analysis at IASP Pain Congress

You may also like

Crypto prices